Emerging in the landscape of obesity treatment, retatrutide is a different strategy. Unlike many current medications, retatrutide functions as a twin agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) binding sites. The concurrent activation promotes various helpful effects, like